Does fesoterodine have a role in the treatment of poorly managed patients with overactive bladder?
Overactive bladder (OAB), a clinically defined symptom complex comprising urinary urgency, usually accompanied by urinary frequency and nocturia, with or without urgency incontinence, is common and has a markedly negative impact on the sufferer's quality of life. Following conservative and lifestyle management, the current pharmacological mainstay of treatment is antimuscarinic therapy. This review explores the role of fesoterodine, a relatively recently introduced antimuscarinic agent, in the treatment of patients who may have had a suboptimal response to initial therapy, who have switched treatment from tolterodine, or may be at risk of receiving poor treatment because of either multimorbidity or complex polypharmacy.
Geriatric Medicine, Taunton Hospital Somerset, UK.
Vikky
V
Morris
Division of Geriatric Medicine, University of Alberta, Edmonton, Alberta, Canada.
Adrian
A
Wagg
D001559:Benzhydryl Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D018727:Muscarinic Antagonists / Q000627:therapeutic use*; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*
D001559:Benzhydryl Compounds; D018727:Muscarinic Antagonists; C526675:fesoterodine
elderly; fesoterodine; overactive bladder; urgency incontinence